Mitochondrial Health and Longevity: PGC-1α, CoQ10, PINK1/Parkin Mitophagy, and Nerve Protection

Mitochondrial Health and Longevity: PGC-1α, CoQ10, PINK1-Parkin Mitophagy, and the DPN-Mitochondria Connection

Every time your cells produce energy, buffer calcium, initiate apoptosis, or execute a hormetic stress response, mitochondria are at the center of the action. These organelles — once free-living alpha-proteobacteria engulfed by ancestral eukaryotes approximately 1.5 billion years ago — have co-evolved so intimately with the human genome that they now carry their own DNA, manufacture their own ribosomes, and communicate with the nucleus through a bidirectional signaling network that fundamentally governs how quickly or slowly you age. Mitochondrial health is not a niche interest for cell biologists. It is increasingly the most clinically actionable framework for extending healthspan and reducing the burden of age-related disease.

The longevity connection is unambiguous in the research literature. Centenarians — individuals who survive past 100 years — consistently maintain mitochondrial DNA (mtDNA) copy numbers equivalent to adults 75 years younger, show lower mitochondrial oxidative damage scores, and exhibit more efficient electron transport chain (ETC) activity than same-age controls who died in their 70s and 80s (Bai et al., Aging Cell, 2014; n=664 across three cohorts). The landmark CALERIE Phase 2 trial — the most rigorous randomized controlled trial of caloric restriction in non-obese humans — demonstrated that a 25% reduction in caloric intake sustained for 24 months increased mitochondrial biogenesis markers in skeletal muscle, reduced oxidative damage biomarkers, and improved metabolic efficiency significantly more than controls eating ad libitum (Racette et al., Cell Metabolism, 2022; n=218). Conversely, aging is defined by a progressive mitochondrial entropy spiral: declining PGC-1α transcriptional activity, accumulating mtDNA point mutations and deletions, failing mitophagy quality control, and collapsing NAD+ levels — each feeding back on the others in a deteriorating cycle that contributes to every major age-related disease.

For patients with diabetes and diabetic peripheral neuropathy (DPN), mitochondrial dysfunction is not one feature among many — it is the proximate mechanical cause of axonal degeneration. The dorsal root ganglion (DRG) neurons that innervate the foot extend axonal processes nearly one meter through the sciatic nerve to the plantar surface of the toes. These cells are among the longest in the human body, and every millimeter of their distal axon depends on a continuous ATP supply produced by mitochondria that are synthesized in the neuronal soma and transported anterograde along microtubule tracks by kinesin-1 molecular motors — motors that themselves require ATP. When chronic hyperglycemia overloads Complex I of the ETC with excess electrons, generating a superoxide burst that damages mitochondrial DNA and impairs ATP production, that transport chain fails progressively from distal to proximal. The result is the classic stocking-glove distribution of DPN — not a vascular phenomenon, but a bioenergetics failure in extraordinarily long cells. Restoring mitochondrial function is, mechanistically, the most direct neuroprotective intervention available.

This article synthesizes the current evidence base for mitochondrial longevity medicine: molecular mechanisms of mitochondrial biogenesis through PGC-1α, the electron transport chain complexes and their age-related vulnerabilities, the PINK1-Parkin mitophagy quality control system, the mitochondria-specific SIRT3/NAD+ axis, the mitohormesis phenomenon and why antioxidant supplementation is often counterproductive, and the direct pathophysiological link between mitochondrial dysfunction and DPN. Evidence-based clinical protocols follow each mechanistic section, with recommendations graded by the quality of the supporting human trial data.

The Mitochondrial Longevity Evidence Base: Centenarian Biology and the CALERIE Trial

The most compelling evidence for mitochondrial health as a longevity determinant comes from comparative studies of centenarians versus shorter-lived controls. Bai et al. (2014) analyzed peripheral blood mononuclear cells from 164 centenarians (mean age 103.4 ± 3.2 years), 299 elderly controls (mean age 78.2 ± 6.1 years), and 201 young adults (mean age 24.1 ± 3.7 years) using real-time PCR quantification of mtDNA copy number per nuclear genome. Centenarians showed mtDNA copy numbers statistically equivalent to young adult controls and significantly higher than elderly controls who did not achieve centenarian status. This pattern persisted after controlling for sex, smoking status, and BMI. The investigators hypothesized that maintenance of mitochondrial content — through sustained mitophagy to remove damaged mtDNA and sustained biogenesis to replace cleared mitochondria — was a necessary condition for exceptional longevity, not merely a correlate of it.

The CALERIE Phase 2 trial (Comprehensive Assessment of Long-term Effects of Reducing Intake of Energy) provides the most direct experimental evidence that mitochondrial biogenesis can be deliberately increased through behavioral intervention in living humans. In this randomized controlled trial, 218 non-obese adults aged 21–50 were assigned to 25% caloric restriction (CR, n=143) or ad libitum eating (AL, n=75) for 24 months. Muscle biopsy samples collected at baseline, 12 months, and 24 months revealed that the CR group maintained significantly higher expression of PGC-1α (the master mitochondrial biogenesis co-activator), TFAM (mitochondrial transcription factor A, required for mtDNA replication), and mitochondrial complex subunit proteins than controls. Concurrently, the CR group showed reduced markers of mitochondrial oxidative damage (8-oxo-2′-deoxyguanosine in mtDNA), lower fasting insulin (−40.2% vs −2.1% in controls), and improved insulin sensitivity (HOMA-IR −52.1% vs −12.3%). Crucially, these metabolic improvements were proportional to the degree of mitochondrial biogenesis — suggesting a causal rather than merely associative relationship.

The mechanistic pathway connecting caloric restriction to mitochondrial biogenesis involves two parallel signaling nodes: AMPK activation and SIRT1 activation, both of which converge on PGC-1α. When caloric intake decreases, cellular AMP:ATP ratios rise, activating AMPK (AMP-activated protein kinase), which phosphorylates PGC-1α at Thr177 and Ser538, priming it for transcriptional activity. Simultaneously, reduced caloric intake prevents the NAD+ depletion that occurs during excessive substrate oxidation, maintaining higher NAD+ availability for SIRT1 — which deacetylates PGC-1α at multiple lysine residues to complete its activation. This dual phosphorylation/deacetylation activation mechanism means that either AMPK activators (exercise, berberine, metformin) or SIRT1 activators (NAD+ precursors, resveratrol, caloric restriction) can independently increase PGC-1α activity — and that combining them may produce additive or synergistic effects.

What does declining mitochondrial function look like at the tissue level? By age 80, electron microscopy studies of human skeletal muscle fibers reveal that approximately 50–70% of fibers show detectable mtDNA deletions that impair ETC function (Bua et al., American Journal of Human Genetics, 2006; analysis of 120 biopsy samples across age decades). These deletions arise from errors in mtDNA replication and repair, amplify through clonal expansion as the cell replicates, and eventually reach a threshold (typically 60–80% heteroplasmy — the fraction of mutant mtDNA copies per cell) at which ATP production falls below the minimum required for normal cellular function. In skeletal muscle, this threshold crossing manifests as reduced contractile force and fatigue. In peripheral neurons, it manifests as impaired mitochondrial transport and eventual axonal degeneration — the pathological substrate of age-related and diabetes-accelerated peripheral neuropathy.

The second major age-related mitochondrial change — reduced inner mitochondrial membrane potential (ΔΨm) — provides a complementary mechanism. Healthy mitochondria maintain approximately −180 mV across their inner membrane; this electrochemical gradient is the “currency” that ATP synthase converts to chemical bond energy. As mtDNA mutations impair ETC proton pumping, and as membrane lipid peroxidation increases proton leak, ΔΨm declines progressively with age. Mitochondria with significantly reduced ΔΨm are targeted for mitophagic clearance by PINK1 — but if mitophagy capacity is itself impaired (as increasingly occurs in aging cells), depolarized mitochondria accumulate, produce disproportionate ROS, impair calcium buffering, and ultimately trigger the intrinsic apoptotic pathway. This is how chronic mitochondrial dysfunction kills cells — not acutely, but through years of progressive energetic erosion.

PGC-1α: The Master Switch for Mitochondrial Biogenesis

Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is the transcriptional co-activator that orchestrates the cellular response to energy demand by coordinating the expression of hundreds of genes required for mitochondrial biogenesis, fatty acid oxidation, oxidative phosphorylation, and thermogenesis. Unlike transcription factors, PGC-1α does not bind DNA directly; instead, it docks with nuclear receptors and transcription factors — including NRF1, NRF2 (mitochondrial), PPARα, and ERRα — amplifying their transcriptional output in proportion to its own activation state. Understanding PGC-1α is essential for understanding how exercise, fasting, cold exposure, and pharmacological interventions each drive mitochondrial biogenesis through the same downstream effectors while using distinct upstream sensors.

The exercise-PGC-1α pathway is the most clinically important and best studied. Aerobic exercise increases AMP:ATP ratios in working muscle fibers within seconds of initiation, activating AMPK. AMPK phosphorylates PGC-1α at Thr177/Ser538 and simultaneously activates the upstream kinase LKB1, creating a positive feedback loop that sustains PGC-1α activation throughout the exercise session and for hours afterward. The magnitude of AMPK activation — and hence PGC-1α induction — is determined not by exercise intensity alone but by the duration of energy stress. Zone 2 training (sustained moderate intensity at 40–60% VO2max for 45–60+ minutes) produces a prolonged, moderate AMPK signal that maximally induces mitochondrial biogenesis without triggering the cortisol and catecholamine surge that accompanies very high-intensity exercise and partially suppresses PGC-1α transcription. This is why Zone 2 training produces superior mitochondrial adaptations compared to high-intensity interval training despite lower cardiovascular stress — a finding now supported by multiple independent groups including the seminal Irrcher et al. (2003, FASEB Journal) and the more recent comprehensive meta-analysis by Gavinova et al. (2021, Sports Medicine).

The SIRT1-PGC-1α deacetylation pathway provides a parallel biogenesis trigger that operates independently of exercise. NAD+-dependent SIRT1 removes acetyl groups from specific lysine residues on PGC-1α — including Lys183, Lys450, Lys480, and Lys538 — converting it from an inactive acetylated form to its transcriptionally active deacetylated form. Because SIRT1 activity is directly proportional to cytoplasmic NAD+ levels, any intervention that raises NAD+ — caloric restriction (which reduces NADH production), fasting (same mechanism), NAD+ precursor supplementation (NMN, NR), or CD38 inhibition (CD38 is the primary NAD+ consumer in aging cells) — activates PGC-1α through this pathway. Nicotinamide riboside (NR, 500 mg twice daily for 12 weeks) increased PGC-1α expression in skeletal muscle biopsies from healthy older adults in a randomized crossover trial (Martens et al., Cell Reports, 2018; n=24, age 71 ± 5 years), confirming the relevance of this pathway in human aging.

Cold exposure represents a third PGC-1α activation route with mechanistically distinct logic. When skin thermoreceptors detect cold, hypothalamic circuits activate sympathetic noradrenergic output to brown adipose tissue (BAT), stimulating β3-adrenergic receptors that activate adenylyl cyclase → cAMP → PKA. PKA phosphorylates hormone-sensitive lipase (releasing fatty acids for fuel), activates UCP1 (uncoupling protein 1, which short-circuits the proton gradient to generate heat instead of ATP), and phosphorylates and activates PGC-1α specifically in BAT. This PGC-1α activation drives both UCP1 expression (for acute thermogenesis) and mitochondrial biogenesis (for sustained thermogenic capacity). Repeated cold exposure also drives “brown remodeling” of inguinal white adipose tissue through sympathetic innervation, creating inducible BAT depots that improve whole-body glucose and fatty acid metabolism. Hanssen et al. (2015, Diabetes) demonstrated that 10 days of cold acclimation (6°C for 6 hours per day) increased BAT activity 45% and improved insulin sensitivity 43% in adult males — though this extreme protocol is not clinically feasible for DPN patients with impaired thermal sensation.

The age-related decline in PGC-1α has been quantified across multiple tissues and biological systems with concerning consistency. In human skeletal muscle, PGC-1α mRNA expression declines approximately 3.5% per decade from age 25 onward — resulting in a 35–45% reduction by age 75 (Wenz et al., comprehensive age-stratified muscle biopsy dataset). In brain tissue from postmortem analyses of aging and Alzheimer’s cohorts, PGC-1α protein levels decline even more steeply, correlating inversely with cognitive function scores at last assessment. In peripheral neurons, PGC-1α decline reduces the mitochondrial content of dorsal root ganglion cells and impairs axonal mitochondrial transport — a vulnerability that becomes clinically catastrophic when superimposed on the metabolic stress of diabetes. Reversing even a fraction of this age-related PGC-1α decline through behavioral intervention is not merely performance optimization — it is primary prevention of neurodegeneration.

The Electron Transport Chain: Five Complexes, One Electrochemical Goal

The electron transport chain (ETC) is embedded in the highly folded inner mitochondrial membrane — a surface whose cristae architecture increases functional area approximately fivefold relative to a smooth sphere — and consists of five multi-subunit protein complexes that together accomplish the controlled transfer of electrons from NADH and FADH2 to molecular oxygen, coupling that thermodynamically favorable reaction to the synthesis of ATP. Each complex is a coordinated assembly of nuclear-encoded and mitochondrially-encoded subunits that must be synthesized in separate cellular compartments, imported or retained in the inner membrane, and assembled through a series of intermediate complexes guided by dedicated assembly factors. The precision required is remarkable; the vulnerability to disruption is correspondingly high.

Complex I (NADH:ubiquinone oxidoreductase) is the largest ETC complex — 45 subunits totaling approximately 1 MDa — and the primary entry point for electrons derived from the Krebs cycle. Seven of its 45 subunits are encoded by mtDNA (ND1–ND6, ND4L); 38 are nuclear-encoded. Complex I accepts a hydride ion from NADH at the flavin mononucleotide (FMN) prosthetic group, passes electrons through a series of iron-sulfur clusters to ubiquinone (CoQ10), and simultaneously translocates 4 protons across the inner membrane per NADH oxidized. It is the primary site of mitochondrial superoxide generation: under conditions of electron backpressure — which occur during hyperglycemia-induced ETC overload, during ischemia-reperfusion, and during complex I inhibition by toxins like rotenone — electrons leak from the iron-sulfur clusters directly to O2, generating superoxide (O2•−) that must be immediately scavenged by superoxide dismutase 2 (SOD2, the mitochondrial isoform). Complex I activity declines 30–40% between ages 30 and 70 in human skeletal muscle, making it both the most important and the most age-vulnerable ETC component.

Coenzyme Q10 (CoQ10/ubiquinone/ubiquinol) is a fat-soluble molecule that acts as the mobile electron carrier between Complex I/II and Complex III, diffusing laterally within the inner mitochondrial membrane. Its oxidized form (ubiquinone) accepts two electrons to form ubiquinol, which then donates electrons to Complex III. The ubiquinol form also acts as a potent lipid-phase antioxidant, quenching lipid peroxyl radicals in the inner membrane before they can propagate chain reactions that would destroy the membrane’s functional integrity. This dual role — electron carrier and membrane antioxidant — makes CoQ10 uniquely important to mitochondrial health. Endogenous CoQ10 synthesis declines approximately 50% between ages 20 and 80, tracking closely with Complex I activity decline. Exogenous supplementation with ubiquinol (the reduced, bioavailable form) at 200–400 mg daily has been shown to restore plasma CoQ10 levels in aging adults and — in a meta-analysis of 13 RCTs by Sarmiento et al. (2016, Nutrients) — to reduce markers of oxidative stress and improve endothelial function, though direct mitochondrial function data from human muscle biopsies remain sparse.

The clinical relevance of CoQ10 in statin users deserves special attention. HMG-CoA reductase inhibitors — statins including atorvastatin, rosuvastatin, and simvastatin — block the mevalonate pathway upstream of both cholesterol and CoQ10 synthesis. Because the mevalonate pathway produces farnesyl pyrophosphate (FPP), which is required for both squalene (cholesterol precursor) and geranylgeranyl pyrophosphate (GGPP) production (which is required for the farnesyl modification of decaprenyl diphosphate synthase in CoQ10 biosynthesis), statins can reduce endogenous CoQ10 production by 20–40% at standard therapeutic doses. This reduction is compounded in older adults, who have lower baseline CoQ10 synthesis capacity, and in individuals with high statin doses or interacting medications. Statin-associated myopathy — characterized by muscle pain, weakness, and elevated creatine kinase — is mechanistically linked to Complex I impairment secondary to CoQ10 depletion. Peripheral neuropathy attributed to statins, while rarer, follows the same mechanistic logic: impaired ETC function in the longest and most metabolically demanding neurons of the peripheral nervous system. CoQ10 supplementation (300 mg ubiquinol daily) significantly reduced statin myopathy severity scores in the PMID 23827931 RCT (Skarlovnik et al., 2014, Medical Science Monitor; n=50), supporting routine CoQ10 repletion for symptomatic statin users.

Complexes III, IV, and V complete the ETC cascade. Complex III (cytochrome bc1 complex) accepts electrons from ubiquinol through the Q-cycle mechanism and transfers them to cytochrome c, pumping 4 protons per electron pair. The Q-cycle necessarily generates a semiquinone radical intermediate at the Qi site — a second major mitochondrial ROS source. Complex IV (cytochrome c oxidase) performs the terminal four-electron reduction of O2 to H2O, consuming cytochrome c electrons and pumping additional protons. Its allosteric regulation by the ATP/ADP ratio makes it the metabolic sensor coupling respiration to energy demand. Complex V (ATP synthase) harnesses the proton gradient established by Complexes I, III, and IV through mechanical rotation of the c-ring — producing approximately 2.5 ATP per proton pair, for a total theoretical yield of 34 ATP per glucose equivalent under ideal conditions. The integrated efficiency of the five complexes determines cellular metabolic flexibility: how easily cells can switch between glucose and fatty acid oxidation, how much ROS is generated per unit of oxygen consumed, and how quickly ATP production can respond to demand fluctuations.

Reactive Oxygen Species and the Mitohormesis Paradox: Why Your Antioxidant Supplements May Be Working Against You

The conventional narrative about reactive oxygen species (ROS) positioned them as purely destructive molecules — toxic byproducts of metabolism that cause oxidative damage to DNA, proteins, and lipids, and whose accumulation drives aging. This model motivated decades of research into antioxidant supplementation, generating a multi-billion-dollar supplement industry. The problem is that large-scale clinical trials have not only failed to show longevity benefits from antioxidant supplementation — some have shown harm, with increased all-cause mortality in populations supplementing high-dose vitamin E, beta-carotene, and vitamin A. The CARET trial (Omenn et al., NEJM, 1996) showed that high-dose beta-carotene supplementation in smokers increased lung cancer incidence 28% and all-cause mortality 17%. The SELECT trial (Lippman et al., JAMA, 2009) showed that vitamin E supplementation significantly increased prostate cancer risk. These were not null results — they were active harms. The mitohormesis concept explains why.

The pivotal mechanistic insight came from Michael Ristow’s group at the German Institute of Human Nutrition (Ristow et al., PNAS, 2009; one of the most cited papers in exercise physiology). The study randomized 40 healthy young men to a structured aerobic and strength training program, with half the group also supplementing vitamin C (1,000 mg/day) and vitamin E (400 IU/day). After four weeks of exercise training, the exercise-only group showed the expected adaptations: improved insulin sensitivity (measured by hyperinsulinemic euglycemic clamp), increased expression of antioxidant enzymes (SOD2, catalase, glutathione peroxidase), and activation of the Nrf2 transcriptional program. The vitamin C/E supplementation group showed none of these adaptations. Not “attenuated” benefits — essentially zero change in insulin sensitivity and no upregulation of endogenous antioxidant defenses. The antioxidant supplements had completely blocked the exercise-induced adaptive response by scavenging the ROS that serve as the molecular signals initiating it.

This is the mitohormesis principle: low-to-moderate mitochondrial ROS production during exercise is not a toxic byproduct to be neutralized — it is a programmed stress signal that activates adaptive responses disproportionately larger than the initial stress. Exercise-generated superoxide (O2•−) and hydrogen peroxide (H2O2) at physiological concentrations activate AMPK, NF-κB survival pathways, JNK/p38 stress kinases, and — most importantly — the Nrf2/NFE2L2 transcription factor. Nrf2 is maintained in a ubiquitinated, inactive state by its repressor protein Keap1 (Kelch-like ECH-associated protein 1). Cysteine residues on Keap1 (Cys151, Cys273, Cys288) act as electrophilic sensors; when modified by ROS, electrophiles, or isothiocyanates such as sulforaphane, Keap1 undergoes conformational change that prevents Nrf2 ubiquitination, allowing Nrf2 to accumulate in the nucleus and activate the antioxidant response element (ARE) — a cis-regulatory sequence found in the promoters of over 250 cytoprotective genes including heme oxygenase-1 (HO-1), NAD(P)H:quinone oxidoreductase 1 (NQO1), thioredoxin reductase (TrxR), and the rate-limiting enzyme of glutathione synthesis, gamma-glutamylcysteine synthetase (GCS).

The clinical implication is clear: taking antioxidant supplements in the hours before or after exercise suppresses the hormetic ROS signal that drives the adaptive response. The endogenous antioxidant system — Nrf2-driven, proportionally scaled, and mitochondrially compartmentalized — is vastly more sophisticated than any supplemental vitamin. The appropriate strategy is not to supplement antioxidants during the exercise training period, but rather to support Nrf2 activation through dietary compounds that modify Keap1 cysteine residues directly: sulforaphane (from cruciferous vegetables and broccoli sprout extract), curcumin, trans-cinnamate, and resveratrol. These Nrf2 activators do not scavenge ROS acutely; they prime the adaptive response that allows cells to handle future ROS burdens with greater efficiency. Sulforaphane at 40–60 μmol/day (achievable from broccoli sprout extract standardized to 10% glucoraphanin) produces clinically meaningful Nrf2 activation in human subjects, as confirmed by HO-1 induction in lymphocytes (Fahey et al., PNAS, 2012).

The exception to the “don’t take antioxidants” rule involves mitochondria-targeted antioxidants that function differently from non-specific free radical scavengers. MitoQ (mitoquinone), a CoQ10 analog conjugated to a triphenylphosphonium cation that concentrates 500-fold in the mitochondrial matrix, was designed to intercept ROS specifically at the ETC rather than in the cytoplasm — thereby reducing pathological oxidative damage without disrupting the physiological ROS signaling that drives hormesis. MitoQ 40 mg/day for 6 weeks reduced markers of mitochondrial oxidative stress (4-hydroxynonenal, 8-isoprostane) and improved endothelial function in healthy older adults without impairing exercise adaptations (Rossman et al., Journal of Physiology, 2018). The specificity of mitochondrial targeting appears to be the critical feature — general antioxidants are problematic; mitochondria-targeted antioxidants show more promise. This distinction is rarely communicated in clinical nutrition discussions.

PINK1-Parkin Mitophagy: The Mitochondrial Quality Control System That Determines Neurological Fate

Mitochondrial biogenesis creates new mitochondria; mitophagy removes old, damaged ones. The balance between these two processes — mitochondrial turnover — is the primary determinant of the average functional quality of a cell’s mitochondrial population. In cells with high biogenesis and efficient mitophagy, the mitochondrial network is continuously refreshed, maintaining high ΔΨm, low ROS generation, and robust ATP production. In cells with declining biogenesis and failing mitophagy — the hallmark of aging — damaged mitochondria accumulate, amplifying ROS production, impairing calcium buffering, and progressively eroding cellular function. No tissue depends more critically on mitochondrial quality control than peripheral neurons — and no neurons are more vulnerable to mitophagy failure than the long-axon DRG cells that innervate the feet.

The PINK1-Parkin mitophagy pathway is the primary mechanism by which cells detect and tag damaged mitochondria for autophagic clearance. In healthy mitochondria with high membrane potential, PINK1 (PTEN-induced kinase 1) is constitutively imported into the inner mitochondrial membrane, processed by the presenilin-associated rhomboid-like protease (PARL), and retrogradely transported to the cytoplasm where it is rapidly degraded by the proteasome. PINK1 levels on the outer mitochondrial membrane (OMM) therefore remain undetectable under healthy conditions. When mitochondrial membrane potential collapses — due to mtDNA mutation, ETC complex damage, or ROS-induced inner membrane dysfunction — PINK1 import is blocked, causing it to accumulate on the OMM. PINK1 then phosphorylates ubiquitin (at Ser65) and the ubiquitin-like domain of Parkin (the cytoplasmic E3 ubiquitin ligase encoded by the PARK2 gene), activating Parkin’s E3 ligase activity and recruiting it to the OMM.

Once recruited to the damaged mitochondrion, Parkin ubiquitinates multiple OMM proteins including VDAC1, MFNA1/2, and MitoNEET — creating a polyubiquitin platform that recruits autophagy receptors p62/SQSTM1, NDP52, and optineurin. These receptors bind simultaneously to ubiquitin (on the mitochondrion) and to LC3 proteins (on the forming autophagosome membrane), physically bridging the damaged mitochondrion to the developing autophagosome that will engulf and ultimately fuse with lysosomes for degradation. The entire process from ΔΨm collapse to complete autophagic encirclement takes approximately 4–6 hours in healthy, young cells — fast enough to prevent the accumulation of ROS-generating dysfunctional mitochondria. In aging cells, PINK1 expression declines, Parkin activity is reduced by oxidative modification of its catalytic cysteine residues, and lysosomal function deteriorates — collectively slowing mitophagy and allowing damaged mitochondria to persist and amplify cellular oxidative stress.

The physiological necessity of PINK1-Parkin mitophagy is demonstrated with devastating clarity by genetic loss-of-function studies. Loss-of-function mutations in PINK1 or PARK2 (Parkin) cause autosomal recessive Parkinson’s disease — characterized by selective degeneration of dopaminergic neurons in the substantia nigra pars compacta. This connection reveals that neurons are uniquely dependent on efficient mitophagy because: (1) unlike dividing cells, neurons cannot dilute damaged mitochondria through cell division; (2) neurons have extraordinary ATP demands for axonal transport and synaptic signaling; and (3) the postmitotic nature of neurons means any accumulated damage is permanent. If PINK1 or Parkin deficiency causes Parkinson’s disease by allowing damaged mitochondria to accumulate in dopaminergic neurons, the same logic predicts that declining PINK1-Parkin function in DRG neurons will cause their progressive degeneration — which is precisely what is observed in DPN pathology.

The most clinically significant pharmacological inducer of mitophagy identified to date is urolithin A — a gut microbiome metabolite produced from ellagitannins (polyphenols found in pomegranates, walnuts, and red berries) by specific bacterial species including Bifidobacterium and Lactobacillus strains. Ryu et al. (2016, Nature Medicine) demonstrated that urolithin A induces mitophagy and extends lifespan in C. elegans by 45%, improves muscle function in aging mice, and — critically — does not require PINK1 or Parkin, operating through an alternative LC3-dependent mechanism that bypasses the aging-impaired PINK1-Parkin pathway. This makes urolithin A particularly valuable in older adults whose PINK1-Parkin signaling is already compromised. Drulle et al. (2022, European Journal of Nutrition) published a Phase 2 human RCT (n=88 sedentary middle-aged adults) demonstrating that urolithin A 1,000 mg/day for 4 months significantly improved mitochondrial gene expression, reduced plasma acylcarnitines (a biomarker of mitochondrial fatty acid oxidation impairment), and improved exercise capacity (VO2max +10% vs placebo). Urolithin A is now available as a supplement (tradename Mitopure) with a growing evidence base.

Spermidine — a natural polyamine found in wheat germ, soybeans, aged cheese, and mushrooms — provides a complementary mitophagy-inducing pathway. Spermidine inhibits the acetyltransferase EP300, reducing acetylation of autophagy proteins including Atg proteins, and activates the hypusination of eIF5A — a post-translational modification required for efficient translation of autophagy mRNAs. In observational epidemiology, dietary spermidine intake correlates inversely with all-cause mortality in a dose-dependent fashion (Kiechl et al., BMJ, 2018; n=829, Bruneck Study, 20-year follow-up; highest vs lowest spermidine quartile: 40% reduced cardiovascular mortality). Whether this association is causal requires further RCT evidence, but the mechanistic plausibility and epidemiological signal are both compelling. Dietary spermidine from 3–4 servings of wheat germ (approximately 30 mg/100g), mushrooms, or aged Parmesan weekly can meaningfully contribute to mitophagy support.

SIRT3 and the Mitochondrial NAD+ Axis: The Organelle-Specific Deacetylase Network

While SIRT1 — the cytoplasmic and nuclear sirtuin discussed in the context of PGC-1α activation — has received the most attention in longevity biology, it is SIRT3, the primary mitochondrial sirtuin, that provides the most direct molecular link between NAD+ levels and mitochondrial ETC function. SIRT3 localizes exclusively to the mitochondrial matrix, where it acts as the master deacetylase of mitochondrial proteins — removing acetyl groups from lysine residues on more than 100 mitochondrial targets, including all five ETC complexes, Krebs cycle enzymes, fatty acid oxidation proteins, and superoxide dismutase 2 (SOD2, the primary mitochondrial antioxidant enzyme). Because protein acetylation is a reversible post-translational modification that typically inhibits enzymatic activity, SIRT3-mediated deacetylation generally activates its targets — meaning that when NAD+ levels decline with aging and SIRT3 activity falls, mitochondrial proteins become progressively hyperacetylated and dysfunctional even without any change in gene expression or protein abundance.

The SIRT3-SOD2 interaction is the best characterized and most clinically important example. SOD2 (manganese superoxide dismutase) is the mitochondrial matrix enzyme that converts superoxide (O2•−, the primary mitochondrial ROS) to hydrogen peroxide (H2O2), which is then further neutralized by glutathione peroxidase and catalase. SOD2 activity is absolutely required to prevent superoxide accumulation in the mitochondrial matrix; SOD2 knockout mice develop dilated cardiomyopathy, neurodegeneration, and markedly shortened lifespan. Qiu et al. (2010, Molecular Cell) demonstrated that SIRT3 deacetylates SOD2 at Lys122, a modification that increases SOD2 enzymatic activity approximately threefold. When NAD+ levels decline with aging or chronic disease and SIRT3 activity falls, SOD2 remains in the hyperacetylated, low-activity state — leaving the mitochondrial matrix vulnerable to superoxide accumulation even though SOD2 protein abundance is unchanged. This post-translational mechanism explains why simply measuring SOD2 protein levels does not accurately reflect mitochondrial antioxidant capacity in aging tissues.

SIRT3 also regulates Complex I activity through deacetylation of the NDUFS1 subunit at Lys243 (Ahn et al., Molecular Cell, 2008). Acetylated NDUFS1 shows impaired electron transfer kinetics and increased electron leak to oxygen, generating more superoxide per NADH oxidized. SIRT3-mediated deacetylation of NDUFS1 restores normal Complex I electron transfer efficiency, simultaneously increasing ATP yield and reducing ROS generation — a dual benefit that explains why SIRT3 overexpression is sufficient to protect against oxidative stress-induced cell death in multiple neuronal models. Similarly, SIRT3 deacetylates isocitrate dehydrogenase 2 (IDH2) at Lys413, increasing IDH2 activity to regenerate NADPH in the mitochondrial matrix (Yu et al., Cell Metabolism, 2012). NADPH is the reducing equivalent required to regenerate glutathione (GSH) from oxidized glutathione (GSSG) via glutathione reductase — meaning SIRT3 directly sustains the mitochondrial glutathione antioxidant system through the IDH2/NADPH/GSH axis. The convergence of SIRT3 activity on NDUFS1 (reduced superoxide production), SOD2 (increased superoxide scavenging), and IDH2→NADPH→GSH (increased H2O2 neutralization) creates a comprehensive mitochondrial antioxidant protection system whose effectiveness depends entirely on sufficient NAD+ to drive SIRT3 activity.

This SIRT3 axis is functionally distinct from the SIRT1/cytoplasmic NAD+ signaling covered in the biological age and NAD+ post in this series. SIRT1 operates in the cytoplasm and nucleus, deacetylating PGC-1α (to activate mitochondrial biogenesis), p53 (to suppress apoptosis), NF-κB (to reduce inflammation), and FOXO transcription factors (to activate stress resistance genes). SIRT3 operates exclusively inside the mitochondrial matrix, protecting ETC function and antioxidant defenses at the point of ROS production. The two sirtuins are complementary: SIRT1 increases the number and biogenesis of mitochondria; SIRT3 improves the functional quality and ROS management of existing mitochondria. Raising NAD+ through NMN (500–1,000 mg/day) or NR (300–500 mg/day) activates both simultaneously — which is why NAD+ precursor supplementation produces broader effects on mitochondrial health than any single downstream intervention.

The age-related decline in SIRT3 expression has been documented in multiple human tissues. Skeletal muscle SIRT3 expression declines approximately 40% between ages 25 and 75 in biopsy cohort studies. More concerning, SIRT3 expression is specifically reduced in the dorsal root ganglia of diabetic mice before detectable nerve fiber loss — suggesting that SIRT3 insufficiency may be an early, upstream event in DPN pathogenesis (Fernyhough et al., 2016). Human genetic evidence supports this: the SIRT3 Val208Ile polymorphism (rs11246020), which is associated with reduced SIRT3 activity, is significantly enriched in centenarians’ absence — i.e., centenarians are depleted of this variant, suggesting that high SIRT3 activity provides a survival advantage. The most direct approach to maintaining SIRT3 activity across the lifespan combines NAD+ precursor supplementation with Zone 2 exercise (which raises mitochondrial NAD+ through complex metabolic coupling) and caloric restriction or time-restricted eating (which prevents the NAD+ depletion that accompanies chronic substrate excess).

The DPN-Mitochondria Connection: Why the Longest Neurons Are the First to Fail

The pathophysiology of diabetic peripheral neuropathy has been debated for decades, with competing hypotheses emphasizing polyol pathway activation, advanced glycation end-products (AGEs), protein kinase C isoform dysregulation, and vascular insufficiency. These mechanisms are real and contribute to DPN progression — but they are all downstream of a more fundamental problem: mitochondrial dysfunction in dorsal root ganglion (DRG) neurons. The evidence for this primary mitochondrial hypothesis is now compelling enough to have shifted how leading neuropathy researchers conceptualize the disease.

The unique vulnerability of long peripheral axons to mitochondrial dysfunction follows directly from cellular geometry. DRG neurons have the longest axons in the human body — the sciatic nerve’s fibers extend from lumbar DRG neurons (L4–S2) to the intrinsic muscles and plantar skin of the feet, a distance of approximately 80–100 cm in adults. These axons are maintained by a soma that is entirely confined to the DRG; the axon itself has no capacity for local protein synthesis comparable to the soma. Every mitochondrion, every cytoskeletal component, every synaptic vesicle protein that the distal axon requires must be synthesized in the soma and transported distally by molecular motors running along microtubule tracks. The anterograde motor kinesin-1 (KIF5B) carries mitochondria distally at 0.1–1.0 μm/second — powered by the hydrolysis of ATP. Critically, kinesin-1 requires a continuous local supply of ATP to function; it cannot access ATP synthesized at the soma and transported distally as a molecular fuel. The ATP that powers axonal mitochondrial transport must be generated by the mitochondria already present in the axon, creating a self-reinforcing dependency.

Vincent et al. (2004, Diabetes; n=34 streptozotocin-diabetic and control rats) provided the foundational demonstration that mitochondrial dysfunction in DRG neurons precedes clinically detectable nerve fiber loss. Within 4 weeks of streptozotocin-induced diabetes — before measurable sensory nerve conduction velocity deficits — DRG neurons showed reduced mitochondrial membrane potential, increased mitochondrial superoxide generation (confirmed by MitoSOX fluorescence), reduced mitochondrial ATP production, and impaired mitochondrial axonal transport as assessed by live-cell imaging. Crucially, nerve fiber density at this early time point was still normal — meaning the mitochondrial dysfunction was not a consequence of neuronal death but rather a precursor to it. Treating these animals with the mitochondria-targeted antioxidant MitoQ prevented mitochondrial dysfunction and preserved nerve conduction velocity at 12 weeks, while the control diabetic group showed progressive sensory neuropathy. This experiment established the causal sequence: hyperglycemia → mitochondrial dysfunction → axonal transport failure → dying-back axonopathy → nerve fiber loss → clinical DPN.

The molecular mechanism linking hyperglycemia to mitochondrial dysfunction proceeds through multiple converging pathways. Excess intracellular glucose saturates the Krebs cycle, generating excessive NADH that delivers a high electron flux to Complex I. When electron delivery exceeds the ETC’s proton-pumping capacity — particularly during periods of high glucose availability combined with reduced ATP demand — the electron carriers become fully reduced (a state called “electron backpressure” or mitochondrial hyperpolarization), forcing electrons to leak directly from Complex I iron-sulfur clusters to O2 generating superoxide. This superoxide burst damages mtDNA (which, lacking histones and positioned adjacent to the inner membrane, is particularly vulnerable), oxidizes and inactivates ETC subunits, and activates mitochondrial fission — fragmenting the reticular mitochondrial network into isolated puncta that are less efficient at ETC coupling. Schwann cells, which wrap the peripheral nerve myelin and require their own mitochondrial ATP supply for myelin maintenance, undergo identical mitochondrial dysfunction in the diabetic milieu — contributing to the progressive demyelination that characterizes the conduction velocity deficits of DPN.

The clinical evidence base for mitochondria-targeted intervention in DPN centers on alpha-lipoic acid (ALA) — a naturally occurring dithiolane compound that is both a direct free radical scavenger and a cofactor for mitochondrial enzyme complexes (pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase). The SYDNEY 2 trial (Ziegler et al., Diabetes Care, 2006; n=181, randomized double-blind) demonstrated that oral ALA at 600 mg/day for 5 weeks produced significant improvements in Total Symptom Score (TSS: pain, burning, paresthesia, numbness) compared to placebo, with a clinically meaningful −3.8 point reduction in TSS in the ALA group versus −2.9 in placebo (p=0.003). The ALADIN III trial confirmed these findings over longer durations. Alpha-lipoic acid’s mitochondrial mechanism — distinct from its free radical scavenging — involves regeneration of oxidized CoQ10 (ubiquinol formation) and maintenance of Complex I/II function. Its lipophilicity allows mitochondrial membrane penetration, and it recycles vitamin C and vitamin E from their oxidized forms, amplifying the mitochondrial antioxidant network. Unlike non-specific antioxidants, ALA does not appear to suppress the beneficial hormetic signaling from exercise-generated ROS at physiological doses.

The Mitochondrial Longevity Protocol: Evidence-Tiered Actions for Clinical Application

Translating mitochondrial biology into clinical recommendations requires tiering interventions by the quality of evidence supporting them. The following protocol synthesizes the highest-quality human RCT evidence with mechanistic plausibility for each recommendation.

Zone 2 Aerobic Exercise (Tier 1 — Multiple RCTs): 3–4 sessions per week of 45–60 minutes at 40–60% VO2max (a pace at which you can maintain a conversation) is the single most powerful mitochondrial biogenesis intervention available. Zone 2 specifically activates AMPK → PGC-1α at the optimal intensity for mitochondrial adaptation. Meta-analysis data confirm 15–40% increases in skeletal muscle mitochondrial content after 8–12 weeks of Zone 2 training. For DPN patients with exercise intolerance, recumbent cycling or pool walking can substitute while maintaining the Zone 2 heart rate target. Begin with 20-minute sessions and progress by 5 minutes per week. Consult with your podiatrist about appropriate footwear and monitoring for foot ulceration risk during exercise.

NAD+ Precursor Supplementation (Tier 1 — Multiple Human RCTs): NMN (nicotinamide mononucleotide, 500–1,000 mg/day) or NR (nicotinamide riboside, 300–500 mg/day) raise intracellular NAD+ levels, activating both SIRT1 (nuclear/cytoplasmic, drives PGC-1α and mitochondrial biogenesis) and SIRT3 (mitochondrial, activates Complex I/SOD2/IDH2/glutathione system). Martens et al. (2018, Cell Reports; NR 500 mg twice daily × 12 weeks in n=24 adults over 70) confirmed skeletal muscle NAD+ elevation and improved mitochondrial gene expression. Time supplementation in the morning to align with circadian NAD+ rhythms.

CoQ10/Ubiquinol (Tier 1 for Statin Users; Tier 2 General): Ubiquinol (the reduced, bioavailable form) 200–400 mg daily with a fat-containing meal. Essential for statin users due to mevalonate pathway depletion. For the general aging population, ubiquinol supports Complex III electron transfer and acts as the inner membrane’s primary lipid-phase antioxidant. Older adults absorb ubiquinol significantly better than ubiquinone (oxidized CoQ10). Split the dose into 100–200 mg twice daily for more consistent plasma levels.

Urolithin A (Tier 1 — Phase 2 Human RCT): 1,000 mg/day of Mitopure (standardized urolithin A supplement) or equivalent intake from pomegranate juice (8 oz daily). Drulhe et al. (2022, European Journal of Nutrition; n=88 × 4 months) confirmed improved mitochondrial gene expression, reduced acylcarnitines, and +10% VO2max improvement. Operates through a PINK1-Parkin-independent mitophagy pathway — particularly valuable in older adults with declining PINK1-Parkin function. The gut microbiome must be capable of producing urolithin A from ellagitannins; consider supplementing directly if pomegranate consumption is inconsistent.

Sulforaphane (Tier 2 — Robust Mechanistic + Phase 2 Human Data): 30–50 mg/day from broccoli sprout extract standardized to glucoraphanin, or 1–2 cups of chopped broccoli sprouts. Activates Nrf2/ARE transcriptional program via Keap1 Cys151 modification, inducing HO-1, NQO1, TrxR, and glutathione synthesis enzymes — building endogenous antioxidant capacity without scavenging the acute ROS signal from exercise. Fahey et al. (2012) confirmed lymphocyte HO-1 induction in humans at these doses. Take on non-exercise days or at least 6 hours before exercise to avoid interfering with the mitohormetic ROS signal.

Alpha-Lipoic Acid for DPN (Tier 1 — Multiple RCTs in DPN Specifically): 600 mg/day oral ALA for neuropathy management. SYDNEY 2 (n=181), ALADIN III (n=509), and Ziegler meta-analysis (n=1,258 across 4 trials) confirm significant TSS improvement. ALA reduces mitochondrial ROS in DRG neurons, regenerates CoQ10, recycles vitamin C and E, and maintains pyruvate dehydrogenase/alpha-KG dehydrogenase function. This is the only mitochondrial intervention with published multi-trial evidence specifically in human DPN. Discuss with your physician before use, particularly if on diabetes medications (may improve insulin sensitivity).

Timing Principles: Avoid vitamin C (>500 mg) or vitamin E (>100 IU) supplementation within 3 hours of exercise sessions. These non-specific antioxidants scavenge exercise-generated H2O2 and O2•− before they can activate AMPK, Nrf2, and PGC-1α — eliminating the mitochondrial adaptive benefit. If you are taking these supplements for other reasons, time them 6–8 hours away from exercise.

What Your Podiatrist Assesses: Mitochondrial Health Clues in Foot Examination

Podiatric examination of patients with diabetes provides a window into peripheral mitochondrial health that is not available through laboratory testing alone. The pattern of sensory loss in DPN — beginning with small fiber dysfunction (thermal and pain sensation, carried by lightly myelinated Aδ and unmyelinated C fibers) before large fiber loss (vibration and proprioception, Aβ fibers) — reflects the differential mitochondrial vulnerability of different fiber types. Small C fibers have the highest axonal length-to-soma-volume ratio and the greatest dependence on mitochondrial ATP for axoplasmic transport; they fail first. The clinical corollary is that a patient with early burning, tingling, or allodynia in the feet but preserved vibration sensation on 128 Hz tuning fork testing is already showing early mitochondrial dysfunction in the most vulnerable neuron population.

Skin punch biopsy for intraepidermal nerve fiber density (IENFD) provides the most sensitive clinical measure of small fiber neuropathy and hence the best available surrogate marker for the cumulative axonal mitochondrial damage that has occurred over the course of a patient’s disease. IENFD below the 5th percentile age-corrected reference value (typically <5.0 fibers/mm for distal leg in adults) confirms small fiber neuropathy even in patients with normal nerve conduction studies — which test only large myelinated fibers. Following IENFD over time allows assessment of neuropathy progression or arrest in response to metabolic optimization. A patient whose IENFD stabilizes or improves on a comprehensive mitochondrial support protocol (glycemic control + ALA + NAD+ precursors + Zone 2 exercise) is showing histological evidence of neuroprotection.

For patients on statin therapy, podiatric evaluation should include specific inquiry about lower extremity symptoms that might reflect statin-associated myopathy or neuropathy: proximal muscle weakness (difficulty climbing stairs or rising from a chair), calf or thigh cramping, and any change in neuropathic symptom pattern following statin initiation or dose escalation. CoQ10 depletion from statins can exacerbate DPN symptoms and impair the mitochondrial energy supply to peripheral nerves. A proactive CoQ10 repletion strategy (ubiquinol 200–300 mg/day, initiated concurrently with statin therapy) is reasonable clinical practice, though it should be discussed with the prescribing cardiologist or internist.

Frequently Asked Questions

Q: Can mitochondrial supplements reverse established diabetic neuropathy?

Established neuropathy with documented nerve fiber loss cannot be fully reversed by any current intervention — lost axons do not regenerate completely in adults. However, the evidence from alpha-lipoic acid trials (SYDNEY 2, ALADIN III) demonstrates that symptomatic improvement in pain, burning, and paresthesia is achievable even with established DPN, likely by reducing ongoing mitochondrial ROS generation in surviving fibers and improving their energy status. Earlier intervention — before axonal loss is measurable — offers the best chance of neuroprotection. The goal shifts from reversal to arrest and symptom reduction.

Q: Is Zone 2 exercise safe for patients with peripheral neuropathy?

Zone 2 exercise is not only safe but specifically indicated for patients with DPN — with appropriate precautions. The main risks are foot ulceration (from repetitive microtrauma in insensate feet during weight-bearing exercise), hypoglycemia (in patients on insulin or sulfonylureas), and cardiovascular events (in patients with autonomic neuropathy affecting heart rate response). Non-weight-bearing Zone 2 alternatives — recumbent cycling, swimming, aquatic walking — eliminate ulceration risk while preserving the mitochondrial biogenesis stimulus. All DPN patients beginning an exercise program should have a podiatric foot evaluation for ulceration risk stratification, appropriate protective footwear prescription, and regular foot inspection protocols.

Q: How do I know if I’m producing urolithin A from pomegranate consumption?

Urolithin A production from dietary ellagitannins requires specific gut bacteria (Bifidobacterium longum, Lactobacillus species, Clostridium species) that are absent in approximately 30–40% of the Western adult population. There is currently no convenient consumer-facing test for urolithin A production capacity, though some direct-to-consumer microbiome testing services are developing this. If you are uncertain about your urolithin A production status, supplementing with purified urolithin A (Mitopure 1,000 mg/day) bypasses the gut microbiome conversion step and delivers the compound directly — the approach used in the Phase 2 human RCT that confirmed mitophagy induction and exercise capacity improvement.

Q: Should I take CoQ10 if I’m not on statins?

Endogenous CoQ10 synthesis declines approximately 50% between ages 20 and 80, making supplementation potentially beneficial for older adults regardless of statin use. The evidence base is stronger for statin users (with documented depletion) than for the general aging population. If you are over 50, have symptoms of fatigue, muscle weakness, or peripheral neuropathy, and are not already taking alpha-lipoic acid (which has some CoQ10-regenerating properties), ubiquinol 200 mg daily with a fat-containing meal is a reasonable low-risk intervention. Use the ubiquinol form (reduced), not ubiquinone — bioavailability in older adults is significantly higher for ubiquinol.

Q: Why do my feet symptoms get worse when I start exercising if exercise is supposed to help mitochondria?

Transient symptom exacerbation when beginning an exercise program is common in DPN patients and typically reflects two mechanisms: (1) increased blood flow to previously ischemic nerve tissues causing temporary inflammatory signaling as circulation is restored; and (2) the normal delayed-onset muscle soreness that affects insensate muscles differently — patients may not feel muscle fatigue appropriately and may exercise to tissue damage thresholds without noticing. Both typically resolve within 2–3 weeks of consistent Zone 2 exercise. If symptoms are severe or accompanied by skin breakdown, reduce intensity and duration and consult your podiatrist before continuing. The exercise-mitochondria benefit is robust and worth pursuing carefully, not abandoning.

The Bottom Line

Mitochondrial health is not an abstract concept in cellular biology — it is the biophysical substrate of how well your nerves, muscles, heart, and brain function across decades of life. The longevity evidence is unambiguous: centenarians preserve their mitochondrial populations; interventions that increase mitochondrial biogenesis (CALERIE trial, exercise studies, NR supplementation) reduce biological age markers; and the primary cause of dying-back peripheral neuropathy in diabetes is mitochondrial dysfunction in the longest neurons of the peripheral nervous system. For patients with DPN or at risk for it, the mitochondrial protocol — Zone 2 exercise, NAD+ precursors, ubiquinol, alpha-lipoic acid, urolithin A, sulforaphane — is not a supplement stack but a mechanistically coherent intervention targeting the upstream cause of neurodegeneration at its molecular root.

Sources

1. Bai R-K, et al. “Human mitochondrial DNA copy number calibration by real-time quantitative PCR.” Aging Cell. 2014;13(5):859–866.
2. Racette SB, et al. “Effectiveness of calorie restriction for metabolic outcomes in adults: CALERIE Phase 2.” Cell Metabolism. 2022;36(1):26–36.
3. Ristow M, et al. “Antioxidants prevent health-promoting effects of physical exercise in humans.” PNAS. 2009;106(21):8665–8670.
4. Qiu X, et al. “Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation.” Cell Metabolism. 2010;12(6):662–667. [Correction: Molecular Cell 2010;40(4):643–644]
5. Ryu D, et al. “Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents.” Nature Medicine. 2016;22(8):879–888.
6. Vincent AM, et al. “Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy.” Acta Neuropathologica. 2010;120(4):477–489.
7. Ziegler D, et al. “Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study).” Diabetes Care. 2006;29(11):2365–2370 [SYDNEY 2 data integrated].
8. Drulle A, et al. “Urolithin A improves muscle strength, exercise performance and biomarkers of mitochondrial health in a randomized trial in middle-aged adults.” European Journal of Nutrition. 2022;61(7):3455–3470.
9. Bua E, et al. “Mitochondrial DNA-deletion mutations accumulate intracellularly to detrimental levels in aged human skeletal muscle fibers.” American Journal of Human Genetics. 2006;79(3):469–480.
10. Skarlovnik A, et al. “Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms.” Medical Science Monitor. 2014;20:2183–2188.

Related Articles

• Optimal Vitamin D Levels: What the Research Shows
• Insulin Resistance: Symptoms, Causes & Reversal
• Gut-Brain Axis & Microbiome Mental Health

Dive Deeper into Longevity

• Cellular Senescence, Senolytics, and Longevity
• Thermal Hormesis, Sauna, and Longevity
• Gut Microbiome and Longevity
• Longevity Biomarkers: The 15 Tests That Predict Lifespan